CD19 and neoplasm: Similar to blinatumomab, downregulation or antigen loss is a common mechanism of tumor escape after anti-CD19 CAR-T cell therapy, with observed CD19-negative relapse rates of 10–25% in several clinical trials [23,24,27,54].